TScan Therapeutics (TCRX) EBIT Margin (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly EBIT Margin of 2967.31% for Q1 2026, down 129757.0% year-over-year from N/an in Q1 2025, and down 219.27% quarter-over-quarter from 929.41% in Q4 2025.
TScan Therapeutics (TCRX) EBIT Margin (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported EBIT Margin for 7 consecutive years, with 2967.31% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT Margin fell 129757.0% year-over-year to 2967.31%; the TTM figure through Mar 2026 stood at 1408.73% (up 175114.0% YoY), while the FY2025 annual figure was 1315.38%, up 347230.0% from the prior year.
- EBIT Margin retreated to 2967.31% in Q1 2026 per TCRX's latest filing, from 929.41% in the prior quarter.
- Across five years, EBIT Margin topped out at 296.17% in Q4 2023 and bottomed at 6364.55% in Q2 2024.
- Historically, EBIT Margin has averaged 1938.22% across 5 years, with a median of 929.41% in 2025.
- Annual changes were most pronounced in 2024 — EBIT Margin tumbled 558279 bps — and 2025, when it surged 510795 bps.
- TScan Therapeutics' EBIT Margin stood at 602.55% in 2022, then soared by 51 bps to 296.17% in 2023, then plunged by 1764 bps to 5520.6% in 2024, then jumped by 83 bps to 929.41% in 2025, then plunged by 219 bps to 2967.31% in 2026.
- Business Quant data shows TCRX's EBIT Margin at 2967.31% in Q1 2026, 929.41% in Q4 2025, and 1475.59% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | TScan Therapeutics | 101.63 Mn | 101.63 Mn | - | -2,901.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,901.33% |
| Mar 31, 2026 | -2,967.31% |
| Dec 31, 2025 | -929.41% |
| Sep 30, 2025 | -1,475.59% |
| Jun 30, 2025 | -1,256.60% |
| Mar 31, 2025 | -1,669.74% |
| Dec 31, 2024 | -5,520.60% |
| Sep 30, 2024 | -3,109.82% |
| Jun 30, 2024 | -6,364.55% |
| Mar 31, 2024 | -5,542.93% |
| Dec 31, 2023 | -296.17% |
| Sep 30, 2023 | -636.69% |
| Jun 30, 2023 | -781.77% |
| Mar 31, 2023 | -392.12% |
| Dec 31, 2022 | -602.55% |
| Sep 30, 2022 | -492.95% |
| Jun 30, 2022 | -375.89% |
| Mar 31, 2022 | -535.02% |
| Dec 31, 2021 | -497.62% |
| Sep 30, 2021 | -656.80% |